ONCOS-102 for mesothelioma is a superior first-line therapy to most other options.
This is the result of a study comparing ONCOS-102, an oncolytic virus, with chemotherapy. Since chemotherapy is the first-approved treatment for mesothelioma, it’s the baseline for testing novel therapies.
At the 30-month check-up, ONCOS-102 reached a median survival of 25 months. Chemotherapy’s median survival was 13.5 months, which is similar to how the systemic therapy performs in other trials.
There were 31 patients in the trial. Twenty received ONCOS-102 plus chemotherapy, and 11 received just chemotherapy drugs.
Opdivo and Yervoy for mesothelioma achieved 18 months median survival. They were approved for malignant pleural mesothelioma by the FDA in 2020 if the tumors aren’t treatable with surgery.
ONCOS-102 must pass further testing, including a larger study with more patients. Phase 1 trials often succeed due to smaller and more controlled pools of patients.
How Does ONCOS-102 Work?
ONCOS-102 splits cancer cells from within and releases antigens for T cells to target. T cells download the antigens, or proteins, and associate them with cancer.
So the novel treatment is a combination of virotherapy and immunotherapy. Virotherapy implants a virus into the tumor environment to attack cancer cells – and leave healthy tissue alone. Immunotherapy helps the immune system, which in this case happens when the antigens from the broken-apart cancer cell are released among T cells and B cells.
“This excellent survival outcome suggests a great promise for ONCOS-102 to benefit mesothelioma patients,” said Dr. Magnus Jaderberg, chief medical officer for the manufacturer of the therapy. “Importantly, we have confirmed that ONCOS-102 is active and effective in highly different types of solid tumors in both early and late lines of therapy. Based on the encouraging patient outcomes and deep mechanistic analysis from the phase 1/2 program, we are currently designing and preparing for the next phase in ONCOS-102 clinical development.”
Dr. Jaderberg joined the Mesothelioma Guide podcast to discuss ONCOS-102, which is manufactured by the Norway-based company Targovax.
The FDA granted fast-track designation to ONCOS-102. This allows more communication between Targovax and the agency.
Sources & Author
- Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma. Biospace. Retrieved from: https://www.biospace.com/article/releases/targovax-asa-oncos-102-achieves-25-0-months-median-overall-survival-in-first-line-mesothelioma/. Accessed: 12/20/2021.
Sources & Author